Cure My Disease

Don't miss your cure!

 Log in / Sign up

PET scans may steer cancer therapy in real time

NCT ID NCT07791329

Knowledge-focused Sponsor: Masaryk Memorial Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This trial tests whether an early PET scan can help doctors choose the right treatment for people with locally advanced oesophago-gastric cancer. Patients receive one round of standard chemotherapy, then a second PET scan. If the tumor shows a strong response, they continue chemotherapy; if not, they switch to chemoradiotherapy. The study also looks at blood and tissue biomarkers to see if they can predict treatment response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FDG-PET imaging and blood/tissue miRNA analysis as biomarkers
What this could lead to
If successful, this could make treatment more personalized, helping patients avoid ineffective chemotherapy and switch to chemoradiotherapy earlier.
What could go wrong
This is a Phase 2 trial with 144 patients, so results may not apply broadly. The biomarker approach may not reliably predict outcomes, and imaging or biopsy procedures carry small risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

144 people

The number who actually took part.

Started

Aug 2018

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age of 18 years or more 2. Not currently participating in another study 3. Able and willing to sign informed consent and to comply with study procedures 4. Biopsy-proven locally advanced resectable oesophago-gastric adenocarcinoma (Siewert I - III) with T3N0, T4N0, T2 - T4N+, stage Ib - IIIc I. Adenocarcinoma of distal part of the oesophagus II. Adenocarcinoma of the real cardia III. Adenocarcinoma of the subcardial stomach 5. Staging procedures include endoscopy, endoscopic ultrasound and FDG-PET 6. Eligible patients have to be fit for platinum-containing chemotherapy 7. Tumours must be potentially R0 resectable tumours during consecutive operation. Exclusion Criteria: 1. Participation in another clinical trial of a therapeutic drug during the past 14 days 2. Addiction to alcohol or drugs 3. Women of child-bearing potential who are not using a commonly accepted effective means of contraception; women of child-bearing potential will have negative blood pregnancy test before enrollment 4. Pregnant women and nursing mothers are not allowed to enroll on this study 5. Eastern Cooperative Oncology Group score \>2 6. Previous or secondary malignancy in past 5 years (Excluding skin cancer and early cervical carcinoma) 7. Life expectancy of less than 3 months 8. Uncontrolled bleeding from the tumour 9. Uncontrolled diabetes 10. Patients are also ineligible if they have undergone previous chemotherapy, radiotherapy, or endoscopic laser therapy for EGJ

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adenocarcinoma - gastroesophageal junction (GEJ) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adenocarcinoma - gastroesophageal junction (GEJ) Gastric adenocarcinoma Gastroesophageal junction (GEJ) adenocarcinoma

Contacts and locations

Locations

  • Masaryk Memorial Cancer Institute

    Brno, 65653, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.